Estimating the efficacy of pharmacogenomics over a lifetime
It is well known that common variants in specific genes influence drug metabolism and response, but it is currently unknown what fraction of patients are given prescriptions over a lifetime that could be contraindicated by their pharmacogenomic profiles. To determine the clinical utility of pharmaco...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1006743/full |
| _version_ | 1797644212107214848 |
|---|---|
| author | Zhan Ye John Mayer Emili J. Leary Terrie Kitchner Richard A. Dart Murray H. Brilliant Scott J. Hebbring |
| author_facet | Zhan Ye John Mayer Emili J. Leary Terrie Kitchner Richard A. Dart Murray H. Brilliant Scott J. Hebbring |
| author_sort | Zhan Ye |
| collection | DOAJ |
| description | It is well known that common variants in specific genes influence drug metabolism and response, but it is currently unknown what fraction of patients are given prescriptions over a lifetime that could be contraindicated by their pharmacogenomic profiles. To determine the clinical utility of pharmacogenomics over a lifetime in a general patient population, we sequenced the genomes of 300 deceased Marshfield Clinic patients linked to lifelong medical records. Genetic variants in 33 pharmacogenes were evaluated for their lifetime impact on drug prescribing using extensive electronic health records. Results show that 93% of the 300 deceased patients carried clinically relevant variants. Nearly 80% were prescribed approximately three medications on average that may have been impacted by these variants. Longitudinal data suggested that the optimal age for pharmacogenomic testing was prior to age 50, but the optimal age is greatly influenced by the stability of the population in the healthcare system. This study emphasizes the broad clinical impact of pharmacogenomic testing over a lifetime and demonstrates the potential application of genomic medicine in a general patient population for the advancement of precision medicine. |
| first_indexed | 2024-03-11T14:27:13Z |
| format | Article |
| id | doaj.art-6cee290281764408a2438a7e3eb10c58 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-11T14:27:13Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-6cee290281764408a2438a7e3eb10c582023-10-31T13:36:35ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-10-011010.3389/fmed.2023.10067431006743Estimating the efficacy of pharmacogenomics over a lifetimeZhan YeJohn MayerEmili J. LearyTerrie KitchnerRichard A. DartMurray H. BrilliantScott J. HebbringIt is well known that common variants in specific genes influence drug metabolism and response, but it is currently unknown what fraction of patients are given prescriptions over a lifetime that could be contraindicated by their pharmacogenomic profiles. To determine the clinical utility of pharmacogenomics over a lifetime in a general patient population, we sequenced the genomes of 300 deceased Marshfield Clinic patients linked to lifelong medical records. Genetic variants in 33 pharmacogenes were evaluated for their lifetime impact on drug prescribing using extensive electronic health records. Results show that 93% of the 300 deceased patients carried clinically relevant variants. Nearly 80% were prescribed approximately three medications on average that may have been impacted by these variants. Longitudinal data suggested that the optimal age for pharmacogenomic testing was prior to age 50, but the optimal age is greatly influenced by the stability of the population in the healthcare system. This study emphasizes the broad clinical impact of pharmacogenomic testing over a lifetime and demonstrates the potential application of genomic medicine in a general patient population for the advancement of precision medicine.https://www.frontiersin.org/articles/10.3389/fmed.2023.1006743/fullPharmacogenenomics and personalised medicineelectronic health record (EHR)drug responceprecision medicineindividualized medicine |
| spellingShingle | Zhan Ye John Mayer Emili J. Leary Terrie Kitchner Richard A. Dart Murray H. Brilliant Scott J. Hebbring Estimating the efficacy of pharmacogenomics over a lifetime Frontiers in Medicine Pharmacogenenomics and personalised medicine electronic health record (EHR) drug responce precision medicine individualized medicine |
| title | Estimating the efficacy of pharmacogenomics over a lifetime |
| title_full | Estimating the efficacy of pharmacogenomics over a lifetime |
| title_fullStr | Estimating the efficacy of pharmacogenomics over a lifetime |
| title_full_unstemmed | Estimating the efficacy of pharmacogenomics over a lifetime |
| title_short | Estimating the efficacy of pharmacogenomics over a lifetime |
| title_sort | estimating the efficacy of pharmacogenomics over a lifetime |
| topic | Pharmacogenenomics and personalised medicine electronic health record (EHR) drug responce precision medicine individualized medicine |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1006743/full |
| work_keys_str_mv | AT zhanye estimatingtheefficacyofpharmacogenomicsoveralifetime AT johnmayer estimatingtheefficacyofpharmacogenomicsoveralifetime AT emilijleary estimatingtheefficacyofpharmacogenomicsoveralifetime AT terriekitchner estimatingtheefficacyofpharmacogenomicsoveralifetime AT richardadart estimatingtheefficacyofpharmacogenomicsoveralifetime AT murrayhbrilliant estimatingtheefficacyofpharmacogenomicsoveralifetime AT scottjhebbring estimatingtheefficacyofpharmacogenomicsoveralifetime |